TD Asset Management Inc Acquires 57,000 Shares of Viridian Therapeutics, Inc. $VRDN

TD Asset Management Inc increased its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 174.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,600 shares of the company’s stock after purchasing an additional 57,000 shares during the period. TD Asset Management Inc owned approximately 0.11% of Viridian Therapeutics worth $1,253,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of VRDN. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares during the last quarter. Rice Hall James & Associates LLC increased its position in Viridian Therapeutics by 579.9% during the first quarter. Rice Hall James & Associates LLC now owns 362,893 shares of the company’s stock valued at $4,892,000 after acquiring an additional 309,518 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in Viridian Therapeutics by 15.1% during the first quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after acquiring an additional 275,000 shares during the last quarter. Nuveen LLC bought a new position in Viridian Therapeutics during the first quarter valued at $3,352,000. Finally, Affinity Asset Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 144.3% in the 1st quarter. Affinity Asset Advisors LLC now owns 390,000 shares of the company’s stock worth $5,257,000 after acquiring an additional 230,386 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. Oppenheimer raised their target price on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday. Needham & Company LLC lowered their target price on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Finally, Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $35.38.

Viridian Therapeutics Stock Down 8.8%

Shares of VRDN opened at $21.90 on Thursday. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a fifty day moving average price of $20.02 and a 200-day moving average price of $16.52. The firm has a market capitalization of $1.79 billion, a P/E ratio of -5.72 and a beta of 0.49. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. During the same period in the prior year, the firm earned ($0.81) earnings per share. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.